PURPOSE: The functional relationship between promoter hypermethylation and gene inactivation has been demonstrated for few genes only. We examined the promoter methylation status of two important tumor suppressor genes APAF-1 and DAPK-1 in bladder cancer as well as the mRNA expression pattern of these two genes for possible correlation between promoter hypermethylation and transcriptional repression. METHODS: The methylation status and mRNA expression levels were related to clinicopathological features in 34 patients with transitional cell carcinoma (TCC) of the bladder with a median clinical follow-up of more than 45 months. Tissue from ten patients with nonmalignant disease served as a control group. Quantitative real-time PCR-based detection methods were used for determination of the normalized index of methylation (NIM) as well as the mRNA expression level. RESULTS: APAF-1 and DAPK-1 methylation and mRNA expression was observed in all tumor and normal control samples investigated. Methylation (NIM) levels were significantly higher in tumor tissue for APAF-1 and DAPK-1, but median mRNA expression levels did not differ significantly comparing tumorous and non tumorous tissue. No correlation between expression levels of APAF-1 and DAPK-1 mRNA and tumor stage or grade was observed. However, in superficial TCC a strong correlation between higher NIM levels and lower mRNA expression of the APAF-1 gene was observed (P = 0.014). CONCLUSIONS: Our results, although preliminary, provide first time in vivo expression analysis of the APAF-1 gene in bladder cancer specimen, suggesting expression control by promoter methylation in early stage tumor disease of the bladder.
PURPOSE: The functional relationship between promoter hypermethylation and gene inactivation has been demonstrated for few genes only. We examined the promoter methylation status of two important tumor suppressor genes APAF-1 and DAPK-1 in bladder cancer as well as the mRNA expression pattern of these two genes for possible correlation between promoter hypermethylation and transcriptional repression. METHODS: The methylation status and mRNA expression levels were related to clinicopathological features in 34 patients with transitional cell carcinoma (TCC) of the bladder with a median clinical follow-up of more than 45 months. Tissue from ten patients with nonmalignant disease served as a control group. Quantitative real-time PCR-based detection methods were used for determination of the normalized index of methylation (NIM) as well as the mRNA expression level. RESULTS:APAF-1 and DAPK-1 methylation and mRNA expression was observed in all tumor and normal control samples investigated. Methylation (NIM) levels were significantly higher in tumor tissue for APAF-1 and DAPK-1, but median mRNA expression levels did not differ significantly comparing tumorous and non tumorous tissue. No correlation between expression levels of APAF-1 and DAPK-1 mRNA and tumor stage or grade was observed. However, in superficial TCC a strong correlation between higher NIM levels and lower mRNA expression of the APAF-1 gene was observed (P = 0.014). CONCLUSIONS: Our results, although preliminary, provide first time in vivo expression analysis of the APAF-1 gene in bladder cancer specimen, suggesting expression control by promoter methylation in early stage tumor disease of the bladder.
Authors: K W Lo; J Kwong; A B Hui; S Y Chan; K F To; A S Chan; L S Chow; P M Teo; P J Johnson; D P Huang Journal: Cancer Res Date: 2001-05-15 Impact factor: 12.701
Authors: L Jia; S M Srinivasula; F T Liu; A C Newland; T Fernandes-Alnemri; E S Alnemri; S M Kelsey Journal: Blood Date: 2001-07-15 Impact factor: 22.113
Authors: C Jerónimo; H Usadel; R Henrique; J Oliveira; C Lopes; W G Nelson; D Sidransky Journal: J Natl Cancer Inst Date: 2001-11-21 Impact factor: 13.506
Authors: Wei-Neng Fu; Francesco Bertoni; Stephen M Kelsey; Suzanne M McElwaine; Finbarr E Cotter; Adrian C Newland; Li Jia Journal: Oncogene Date: 2003-01-23 Impact factor: 9.867
Authors: A Satoh; M Toyota; F Itoh; T Kikuchi; T Obata; Y Sasaki; H Suzuki; A Yawata; M Kusano; M Fujita; M Hosokawa; K Yanagihara; T Tokino; K Imai Journal: Br J Cancer Date: 2002-06-05 Impact factor: 7.640
Authors: Lorenzo Galluzzi; Federico Pietrocola; José Manuel Bravo-San Pedro; Ravi K Amaravadi; Eric H Baehrecke; Francesco Cecconi; Patrice Codogno; Jayanta Debnath; David A Gewirtz; Vassiliki Karantza; Alec Kimmelman; Sharad Kumar; Beth Levine; Maria Chiara Maiuri; Seamus J Martin; Josef Penninger; Mauro Piacentini; David C Rubinsztein; Hans-Uwe Simon; Anne Simonsen; Andrew M Thorburn; Guillermo Velasco; Kevin M Ryan; Guido Kroemer Journal: EMBO J Date: 2015-02-23 Impact factor: 11.598
Authors: Mariana Brait; Shahnaz Begum; André L Carvalho; Santanu Dasgupta; André L Vettore; Bogdan Czerniak; Otávia L Caballero; William H Westra; David Sidransky; Mohammad Obaidul Hoque Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-10 Impact factor: 4.254